EORTC studies opened since 15 December 2010
23 Feb 2011
Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with Newly Diagnosed Anaplastic Oligodendroglioma or Anaplastic Mixed Glioma with Chromosomal Co-delections of 1p and 19q
Target Accrual: 544 patients
Study Coordinators:
- Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam
- Frederic Dhermain – Institut Gustave Roussy, Villejuif
- Wolfgang Wick – Universitaetsklinikum Heidelberg – Kopfklinik, Heidelberg
Clinical and biological characterization of Male Breast Cancer: an international retrospective EORTC, BIG and NABCG intergroup study
Target Accrual: 1800 patients
Study Coordinator:
- Fatima Cardoso – Institut Jules Bordet – Brussels
Randomized trial assessing the significance of Bevacizumab in recurrent grade II and grade III gliomas
Target Accrual: 144 patients
Study Coordinators:
- Martin van den Bent – Erasmus University Medical Center, Rotterdam
- Ahmed Idbaih – CHU Pitié-Salpêtrière, Paris
EORTC studies to be opened in 2011 (in regulatory process)
Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL)
Target Accrual: This trial is a prospective observational – biobanking study.
Study Coordinators:
- Helene Cave, Hôpital Robert Debre (AP-HP), Paris
- Yves Benoit, Universiteit Gent, Gent
Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
Target Accrual: 800 patients for the main study, 150 patients for the pre-study
Study Coordinators:
- Wilfried Budach – Heinrich-Heine Universitaetsklinik Dusseldorf, Duesseldorf
- Johannes Langendijk – University Medical Center Groningen, Groningen
- Carla Van Herpen – Radboud University Nijmegen Medical Center, Nijmegen
A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Target Accrual: 340 patients
Study Coordinator:
- Binh Bui-Nguyen – Institut Bergonie, Bordeaux
Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma
Target Accrual: 249 patients
Study Coordinator:
- Wolfgang Wick – UniversitaetsKlinikum Heidelberg – Kopfklinik, Heidelberg
EORTC trial 58LAE (Late Adverse Events)
Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998
Target Accrual: 3138 patients
Study Coordinator:
- Caroline Piette – Centre Hospitalier Regional De La Citadelle, Liege
Empirical versus pre-emptive antifungal therapy in patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups
Target Accrual: 556 patients
Study Coordinator:
- Peter Donnelly – Radboud University Nijmegen Medical Centre, Nijmegen
EORTC trial 06083 HOVON 100 ALL
Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial
Target Accrual: – patients
Study Coordinator:
- Jean-Pierre Marie – Hopital Saint Antoine AP-HP, Paris
Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy
Target Accrual: 587 patients
Study Coordinator:
- Mary O’Brien – Royal Marsden Hospital, Sutton
John Bean
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023